Literature DB >> 26445

Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.

D J Boullin, P A Glenton.   

Abstract

1 Blood platelets from normal human volunteers were isolated and aggregated in vitro with 5-hydroxytryptamine (5-HT), noradrenaline (NA), dopamine and N-dimethyldopamine (DMDA). 2 The effects of 5-HT antagonists, alpha- and beta-adrenoceptor blocking agents, butyrophenones and chlorpromazine upon aggregation induced by the four amines were investigated. 3 Only the the 5-HT antagonists, chlorpromazine and spiroperidol were potent inhibitors of 5-HT-induced aggregation, and only phentolamine was a potent inhibitor of the catecholamine-induced aggregation. 4 Evidence was obtained for two populations of receptors, one for 5-HT and one for the three catecholamines.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 26445      PMCID: PMC1668039          DOI: 10.1111/j.1476-5381.1978.tb07758.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  PLATELET CLUMPING IN VITRO.

Authors:  J R MITCHELL; A A SHARP
Journal:  Br J Haematol       Date:  1964-01       Impact factor: 6.998

2.  Effects of intracranial dopamine perfusion: behavioural arousal and reversal of cerebral arterial spasm following surgery for clipping of ruptured cerebral aneurysms.

Authors:  D J Boullin; C B Adams; J Mohan; A R Green; T M Hunt; G H du Boulay; A T Rogers
Journal:  Proc R Soc Med       Date:  1977

Review 3.  Cardiovascular and renal actions of dopamine: potential clinical applications.

Authors:  L I Goldberg
Journal:  Pharmacol Rev       Date:  1972-03       Impact factor: 25.468

4.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

5.  Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.

Authors:  D J Boullin; D G Grahame-Smith; R P Grimes; H F Woods
Journal:  Br J Pharmacol       Date:  1975-01       Impact factor: 8.739

6.  Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor.

Authors:  D G Grahame-Smith
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

7.  A COMPARISON OF PLATELET AGGREGATION PRODUCED BY SEVEN COMPOUNDS AND A COMPARISON OF THEIR INHIBITORS.

Authors:  J R O'BRIEN
Journal:  J Clin Pathol       Date:  1964-05       Impact factor: 3.411

8.  The effects of dopamine on human platelet aggregation, in vitro.

Authors:  K M Braunstein; K E Sarji; J Kleinfelder; H B Schraibman; J A Colwell; K Eurenius
Journal:  J Pharmacol Exp Ther       Date:  1977-02       Impact factor: 4.030

9.  Relative activities on and uptake by human blood platelets of 5-hydroxytryptamine and several analogues.

Authors:  G V Born; K Juengjaroen; F Michal
Journal:  Br J Pharmacol       Date:  1972-01       Impact factor: 8.739

10.  Two kinds of tryptamine receptor.

Authors:  J H GADDUM; Z P PICARELLI
Journal:  Br J Pharmacol Chemother       Date:  1957-09
View more
  9 in total

1.  Aetiology of cerebral arterial spasm following subarachnoid haemorrhage: evidence against a major involvement of 5-hydroxy-tryptamine in the production of acute spasm.

Authors:  D J Boullin; G H Du Boulay; A T Rogers
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

2.  Agonistic and antagonistic effects of various alpha-adrenergic agonists in human platelets.

Authors:  P Lasch; K H Jakobs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-03       Impact factor: 3.000

3.  Long-term low dose haloperidol treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR, and clinical response.

Authors:  M G Grimaldi
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

4.  Platelet aggregation and chlorpromazine therapy.

Authors:  D J Boullin; J M Know; J R Peters; M W Orr; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

5.  Platelet shape change in patients with psychiatric disorders and treated with phenothiazines, thioxanthines, butyrophenones, benzodiazepines, tricyclic antidepressants and beta-adrenergic blocking agents.

Authors:  D J Boullin
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

6.  The binding of haloperidol to human blood platelets and interactions with 5-hydroxytryptamine and dopamine.

Authors:  D J Boullin; D Molyneux; B Roach
Journal:  Br J Pharmacol       Date:  1978-07       Impact factor: 8.739

7.  Shape change of blood platelets--a model for cerebral 5-hydroxytryptamine receptors?

Authors:  M Graf; A Pletscher
Journal:  Br J Pharmacol       Date:  1979-04       Impact factor: 8.739

8.  Platelet release reaction and aggregation induced by canatoxin, a convulsant protein: evidence for the involvement of the platelet lipoxygenase pathway.

Authors:  C R Carlini; J A Guimarães; J M Ribeiro
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

9.  Recent developments on dry eye disease treatment compounds.

Authors:  Basilio Colligris; Hanan Awad Alkozi; Jesus Pintor
Journal:  Saudi J Ophthalmol       Date:  2013-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.